Developing the next generation FDA approved synthetic THC analog
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is an early-stage life sciences company focused on the development and commercialization of MIRA1a, a synthetic analog of THC. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with cannabis plant extracts.
Investor Relations
MZ North America
Michael Kim / Brooks Hamilton
T: 737-289-0835
MIRA@mzgroup.us
https://www.mzgroup.us
Company Contact
MIRA Pharmaceuticals, Inc.
855 North Wolfe Street
Suite 601
Baltimore, MD 21205
United States
T: 737-289-0835
info@mirapharma.com